<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03323216</url>
  </required_header>
  <id_info>
    <org_study_id>16-132</org_study_id>
    <nct_id>NCT03323216</nct_id>
  </id_info>
  <brief_title>BIO-2-HEART: Identification of Biomarkers in T2DM and Heart Failure</brief_title>
  <acronym>BIO-2-HEART</acronym>
  <official_title>BIO-2-HEART Study (Identifying New BIOmarkers in Patients With Type 2 Diabetes Mellitus and HEArt Failure Receiving Cardiac Resynchronization Therapy Device Implantation)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RWTH Aachen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RWTH Aachen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of the current study is a better understanding of the role of Type 2 Diabetes
      Mellitus (T2DM) in heart failure and, in particular, changes in cardiac metabolism, which may
      contribute to heart failure. Various biomarkers in the coronary artery blood, as well as in
      the arterial and peripheral venous blood, are to be identified for this purpose. Included are
      patients with and without T2DM, who have a clinically indicated and guidance-appropriate
      Cardiac Resynchronisation Therapy (CRT) implantation due to their cardiac insufficiency.

      Not all patients currently benefit from the implantation of a CRT system (so-called
      non-responder). Despite narrow inclusion criteria, these &quot;non-responders&quot; cannot be unmasked
      in advance of the implantation. A further aim of this study is to identify biomarkers, which
      can be determined in advance of implantation to differentiate between responders and
      non-responders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary aim of the current study is a better understanding of the role of Type 2 Diabetes
      Mellitus (T2DM) in heart failure and, in particular, changes in cardiac metabolism, which may
      contribute to heart failure. Various biomarkers in the coronary artery blood, as well as in
      the arterial and peripheral venous blood, are to be identified for this purpose. Included are
      patients with and without T2DM, who have a clinically indicated and guidance-appropriate
      Cardiac Resynchronisation Therapy (CRT) implantation due to their cardiac insufficiency.

      Not all patients currently benefit from the implantation of a CRT system (so-called
      non-responder). Despite narrow inclusion criteria, these &quot;non-responders&quot; cannot be unmasked
      in advance of the implantation. Thus, a further aim of this study is to identify biomarkers,
      which can be determined in advance of implantation to differentiate between responders and
      non-responders.

      Patient selection is based on the previously defined inclusion and exclusion criteria. The
      patient is informed by the physician and gives written consent to participate in the study.
      Prior to the implantation of the CRT system, the patient first responds to a study-related
      questionnaire and performs a 6-minute walk test.

      Afterwards the clinically indicated, elective CRT implantation is performed by experienced
      physicians of the Medical Clinic I. Routinely, an arterial pressure catheter for invasive
      blood pressure monitoring (usually arteria radialis) is inserted. In addition, 2 peripheral
      venous accesses are established. The system of the CRT system is carried out via a small
      pectoral section. The cardiac probes are inserted into the heart via the subclavian vein.
      First, the probe is implanted in the right ventricle and, if necessary, a probe is placed in
      the right atrium.

      To establish the coronary sinus (CS) probe, the intubation of the coronary sinus is performed
      by means of a guide catheter, which can be used to take blood samples. After intubation of
      the coronary sinus, the coronary artery blood is taken from the guide catheter for the study
      as well as arterially via the underlying pressure catheter as well as peripheral venous over
      a horizontal venous catheter. The blood sampling does not take more than 1-2 minutes.

      The surgery is then terminated as planned and postoperative care is performed according to
      the standard operation procedure (SOP) of the Medical Clinic I. Within the framework of a
      control visit routinely performed in the Medical Clinic I , an echocardiographic follow-up of
      heart failure, a history assessment and a laboratory-based blood analysis are performed 6
      months after CRT implantation. In the context of this visit peripheral venous blood is
      collected again for the study. In addition, the 6-minute walk test is performed once more and
      the patient receives the same questionnaire again.

      Laboratory routine blood analysis is performed in the central laboratory of the University
      Hospital of Aachen and is independent of the study. The analysis measures standard parameters
      such as electrolytes, blood count, retention parameters, glucose, HbA1c, liver values,
      N-terminal Brain Natriuretic Peptide (NT-pro-BNP) etc. .

      A blood gas analysis of the study blood is performed out first. The remaining blood is
      processed and stored at -80 Â° C, so-called &quot;biobank&quot;, for further biomarker analysis, e.g.
      metabolite analysis, peptides/proteins and RNA.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Anticipated">March 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Oxygen partial pressure (pO2) [mmHg]</measure>
    <time_frame>Directly prior to the CRT-implantation</time_frame>
    <description>Results of blood gas analysis:
Oxygen partial pressure (pO2) [mmHg]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxygen partial pressure (pO2) [mmHg]</measure>
    <time_frame>6 months after CRT-implantation</time_frame>
    <description>Results of blood gas analysis:
Oxygen partial pressure (pO2) [mmHg]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Carbon dioxide partial pressure (pCO2) [mmHg]</measure>
    <time_frame>Directly prior to the CRT-implantation</time_frame>
    <description>Results of blood gas analysis:
Carbon dioxide partial pressure (pCO2) [mmHg]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Carbon dioxide partial pressure (pCO2) [mmHg]</measure>
    <time_frame>6 months after CRT-implantation</time_frame>
    <description>Results of blood gas analysis:
Carbon dioxide partial pressure (pCO2) [mmHg]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>potential of hydrogen (pH) value [-]</measure>
    <time_frame>Directly prior to the CRT-implantation</time_frame>
    <description>Results of blood gas analysis:
pH value [-]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>potential of hydrogen (pH) value [-]</measure>
    <time_frame>6 months after CRT-implantation</time_frame>
    <description>Results of blood gas analysis:
pH value [-]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Base excess [mmol]</measure>
    <time_frame>Directly prior to the CRT-implantation</time_frame>
    <description>Results of blood gas analysis:
Base excess [mmol]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Base excess [mmol]</measure>
    <time_frame>6 months after CRT-implantation</time_frame>
    <description>Results of blood gas analysis:
Base excess [mmol]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lactate [mmol/l]</measure>
    <time_frame>Directly prior to the CRT-implantation</time_frame>
    <description>Results of blood gas analysis:
Lactate [mmol/l]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lactate [mmol/l]</measure>
    <time_frame>6 months after CRT-implantation</time_frame>
    <description>Results of blood gas analysis:
Lactate [mmol/l]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glucose [mg/dl]</measure>
    <time_frame>Directly prior to the CRT-implantation</time_frame>
    <description>Results of blood gas analysis:
Glucose [mg/dl]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glucose [mg/dl]</measure>
    <time_frame>6 months after CRT-implantation</time_frame>
    <description>Results of blood gas analysis:
Glucose [mg/dl]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrolytes (K+, Na2+, Ca2+) [mmol/l]</measure>
    <time_frame>Directly prior to the CRT-implantation</time_frame>
    <description>Results of blood gas analysis:
Electrolytes (K+, Na2+, Ca2+) [mmol/l]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrolytes (K+, Na2+, Ca2+) [mmol/l]</measure>
    <time_frame>6 months after CRT-implantation</time_frame>
    <description>Results of blood gas analysis:
Electrolytes (K+, Na2+, Ca2+) [mmol/l]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>High-sensitive troponin T [Âµg/L]</measure>
    <time_frame>Directly prior to the CRT-implantation</time_frame>
    <description>Markers of myocardial ischemia and heart failure:
High-sensitive troponin T [Âµg/L]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>High-sensitive troponin T [Âµg/L]</measure>
    <time_frame>6 months after CRT-implantation</time_frame>
    <description>Markers of myocardial ischemia and heart failure:
High-sensitive troponin T [Âµg/L]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total creatine kinase [Âµg/L]</measure>
    <time_frame>Directly prior to the CRT-implantation</time_frame>
    <description>Markers of myocardial ischemia and heart failure:
Total creatine kinase [Âµg/L]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total creatine kinase [Âµg/L]</measure>
    <time_frame>6 months after CRT-implantation</time_frame>
    <description>Markers of myocardial ischemia and heart failure:
Total creatine kinase [Âµg/L]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Creatinine kinase-myocardial band (CK-MB) [Âµg/L]</measure>
    <time_frame>Directly prior to the CRT-implantation</time_frame>
    <description>Markers of myocardial ischemia and heart failure:
Creatinine kinase-myocardial band (CK-MB) [Âµg/L]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Creatinine kinase-myocardial band (CK-MB) [Âµg/L]</measure>
    <time_frame>6 months after CRT-implantation</time_frame>
    <description>Markers of myocardial ischemia and heart failure:
Creatinine kinase-myocardial band (CK-MB) [Âµg/L]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aspartate aminotransferase [Âµg/L]</measure>
    <time_frame>Directly prior to the CRT-implantation</time_frame>
    <description>Markers of myocardial ischemia and heart failure:
Aspartate aminotransferase [Âµg/L]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aspartate aminotransferase [Âµg/L]</measure>
    <time_frame>6 months after CRT-implantation</time_frame>
    <description>Markers of myocardial ischemia and heart failure:
Aspartate aminotransferase [Âµg/L]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lactate dehydrogenase [Âµg/L]</measure>
    <time_frame>Directly prior to the CRT-implantation</time_frame>
    <description>Markers of myocardial ischemia and heart failure:
Lactate dehydrogenase [Âµg/L]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lactate dehydrogenase [Âµg/L]</measure>
    <time_frame>6 months after CRT-implantation</time_frame>
    <description>Markers of myocardial ischemia and heart failure:
Lactate dehydrogenase [Âµg/L]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>N-terminal pro-B-type natriuretic peptide (NT-proBNP) [Âµg/L]</measure>
    <time_frame>Directly prior to the CRT-implantation</time_frame>
    <description>Markers of myocardial ischemia and heart failure:
N-terminal pro-B-type natriuretic peptide (NT-proBNP) [Âµg/L]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>N-terminal pro-B-type natriuretic peptide (NT-proBNP) [Âµg/L]</measure>
    <time_frame>6 months after CRT-implantation</time_frame>
    <description>Markers of myocardial ischemia and heart failure:
N-terminal pro-B-type natriuretic peptide (NT-proBNP) [Âµg/L]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>High-sensitive C-reactive protein (CRP) [Âµg/L]</measure>
    <time_frame>Directly prior to the CRT-implantation</time_frame>
    <description>Cytokines and inflammation markers:
High-sensitive C-reactive protein (CRP) [Âµg/L]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>High-sensitive C-reactive protein (CRP) [Âµg/L]</measure>
    <time_frame>6 months after CRT-implantation</time_frame>
    <description>Cytokines and inflammation markers:
High-sensitive C-reactive protein (CRP) [Âµg/L]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Procalcitonin (PCT) [Âµg/L]</measure>
    <time_frame>Directly prior to the CRT-implantation</time_frame>
    <description>Cytokines and inflammation markers:
Procalcitonin (PCT) [Âµg/L]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Procalcitonin (PCT) [Âµg/L]</measure>
    <time_frame>6 months after CRT-implantation</time_frame>
    <description>Cytokines and inflammation markers:
Procalcitonin (PCT) [Âµg/L]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interleukin 6 (IL-6) [Âµg/L]</measure>
    <time_frame>Directly prior to the CRT-implantation</time_frame>
    <description>Cytokines and inflammation markers:
Interleukin 6 (IL-6) [Âµg/L]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interleukin 6 (IL-6) [Âµg/L]</measure>
    <time_frame>6 months after CRT-implantation</time_frame>
    <description>Cytokines and inflammation markers:
Interleukin 6 (IL-6) [Âµg/L]</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Heart Failure</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>No diabetes</arm_group_label>
    <description>Patients without diabetes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Type 2 diabetes</arm_group_label>
    <description>Patients with diagnosis of type 2 diabetes (new/established)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prediabetes</arm_group_label>
    <description>Patients with an intermediate state of hyperglycemia with glycemic parameters above normal but below the diabetes threshold.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>6-minute walk test</intervention_name>
    <description>The 6-minute walk test is a functional test established in the clinic to assess the performance of a patient. The patient walks continuously for 6 minutes without interruption as far as possible. Breaks, speed changes and running are allowed.
Test is performed prior the CRT implantation and 6 months after the CRT implantation.</description>
    <arm_group_label>No diabetes</arm_group_label>
    <arm_group_label>Type 2 diabetes</arm_group_label>
    <arm_group_label>Prediabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Study specific questionnaire</intervention_name>
    <description>Study specific questionnaire
The questionnaire is performed prior the CRT implantation and 6 months after the CRT implantation.</description>
    <arm_group_label>No diabetes</arm_group_label>
    <arm_group_label>Type 2 diabetes</arm_group_label>
    <arm_group_label>Prediabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood collection</intervention_name>
    <description>Blood collection during surgery:
coronary sinus
arterial
peripheral venous
Blood collection 6 months after surgery:
- peripheral venous</description>
    <arm_group_label>No diabetes</arm_group_label>
    <arm_group_label>Type 2 diabetes</arm_group_label>
    <arm_group_label>Prediabetes</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with heart failure (HFrEF) plus known status of type 2 diabetes (yes/no)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. guideline-appropriate clinical indication for CRT implantation

          2. age of majority

          3. written declaration of consent

          4. persons who are able to work and mentally able to follow the instructions of the study
             staff

          5. free access routes

        Exclusion Criteria:

          1. anemia Hb &lt;8 mg / dl

          2. patients with acute infectious disease (e.g. pneumonia)

          3. non-intubatable coronary sinus

          4. patients who do not have access to the subclavian vein (e.g. thrombosis of the
             subclavian vein or superior vena cava)

          5. patients with idiopathic hypertrophic, restrictive or constrictive cardiomyopathy, or
             heart failure due to a known inflammatory or infiltrating disease (e.g. amyloidosis,
             sarcoidosis) or a constrictive disease

          6. patients with heart failure by sepsis

          7. persons with acute myocardial ischaemia, e.g. by angina pectoris or ECG changes under
             load

          8. patients with acute coronary syndrome are not implanted in the past 3 months

          9. patients who were hospitalized during the last month due to heart failure and who had
             to be treated intravenously with diuretics or inotropic substances

         10. patients with mechanical aortic valve or tricuspid valve

         11. patients with heart transplant.

         12. patients with acute liver or renal failure

         13. pregnant and lactating women

         14. patients placed under an official or judicial order in an institution

         15. patients who are in a dependency or employment relationship with the sponsor or
             auditor

         16. taking an investigational medicinal product 30 days before the start of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ben Kappel, MD PhD</last_name>
    <phone>0241 80 36573</phone>
    <email>bakppel@ukaachen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christina Kalvelage, M. Sc.</last_name>
    <phone>0241 80 36485</phone>
    <email>ckalvelage@ukaachen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <state>NRW</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ben A Kappel, MD PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, GonzÃ¡lez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; ESC Scientific Document Group . 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016 Jul 14;37(27):2129-2200. doi: 10.1093/eurheartj/ehw128. Epub 2016 May 20. Erratum in: Eur Heart J. 2016 Dec 30;:.</citation>
    <PMID>27206819</PMID>
  </reference>
  <reference>
    <citation>Askoxylakis V, Thieke C, Pleger ST, Most P, Tanner J, Lindel K, Katus HA, Debus J, Bischof M. Long-term survival of cancer patients compared to heart failure and stroke: a systematic review. BMC Cancer. 2010 Mar 22;10:105. doi: 10.1186/1471-2407-10-105. Review.</citation>
    <PMID>20307299</PMID>
  </reference>
  <reference>
    <citation>Bahtiyar G, Gutterman D, Lebovitz H. Heart Failure: a Major Cardiovascular Complication of Diabetes Mellitus. Curr Diab Rep. 2016 Nov;16(11):116. Review.</citation>
    <PMID>27730517</PMID>
  </reference>
  <reference>
    <citation>Kappel BA, Marx N, Federici M. Oral hypoglycemic agents and the heart failure conundrum: Lessons from and for outcome trials. Nutr Metab Cardiovasc Dis. 2015 Aug;25(8):697-705. doi: 10.1016/j.numecd.2015.06.006. Epub 2015 Jun 18. Review.</citation>
    <PMID>26164634</PMID>
  </reference>
  <reference>
    <citation>Sun H, Guan Y, Wang L, Zhao Y, Lv H, Bi X, Wang H, Zhang X, Liu L, Wei M, Song H, Su G. Influence of diabetes on cardiac resynchronization therapy in heart failure patients: a meta-analysis. BMC Cardiovasc Disord. 2015 Mar 21;15:25. doi: 10.1186/s12872-015-0018-0. Review.</citation>
    <PMID>25880202</PMID>
  </reference>
  <reference>
    <citation>Watson CJ, Ledwidge MT, Phelan D, Collier P, Byrne JC, Dunn MJ, McDonald KM, Baugh JA. Proteomic analysis of coronary sinus serum reveals leucine-rich Î±2-glycoprotein as a novel biomarker of ventricular dysfunction and heart failure. Circ Heart Fail. 2011 Mar;4(2):188-97. doi: 10.1161/CIRCHEARTFAILURE.110.952200. Epub 2011 Jan 31.</citation>
    <PMID>21282491</PMID>
  </reference>
  <reference>
    <citation>Truong QA, Januzzi JL, Szymonifka J, Thai WE, Wai B, Lavender Z, Sharma U, Sandoval RM, Grunau ZS, Basnet S, Babatunde A, Ajijola OA, Min JK, Singh JP. Coronary sinus biomarker sampling compared to peripheral venous blood for predicting outcomes in patients with severe heart failure undergoing cardiac resynchronization therapy: the BIOCRT study. Heart Rhythm. 2014 Dec;11(12):2167-75. doi: 10.1016/j.hrthm.2014.07.007. Epub 2014 Jul 8.</citation>
    <PMID>25014756</PMID>
  </reference>
  <reference>
    <citation>Costello-Boerrigter LC, Lapp H, Boerrigter G, Lerman A, Bufe A, Macheret F, Heublein DM, Larue C, Burnett JC Jr. Secretion of prohormone of B-type natriuretic peptide, proBNP1-108, is increased in heart failure. JACC Heart Fail. 2013 Jun;1(3):207-12. doi: 10.1016/j.jchf.2013.03.001. Epub 2013 Jun 3.</citation>
    <PMID>24621871</PMID>
  </reference>
  <reference>
    <citation>Marques FZ, Vizi D, Khammy O, Mariani JA, Kaye DM. The transcardiac gradient of cardio-microRNAs in the failing heart. Eur J Heart Fail. 2016 Aug;18(8):1000-8. doi: 10.1002/ejhf.517. Epub 2016 Apr 12.</citation>
    <PMID>27072074</PMID>
  </reference>
  <reference>
    <citation>Bergman BC, Tsvetkova T, Lowes B, Wolfel EE. Myocardial glucose and lactate metabolism during rest and atrial pacing in humans. J Physiol. 2009 May 1;587(Pt 9):2087-99. doi: 10.1113/jphysiol.2008.168286. Epub 2009 Mar 16.</citation>
    <PMID>19289551</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2017</study_first_submitted>
  <study_first_submitted_qc>October 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2017</study_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>RWTH Aachen University</investigator_affiliation>
    <investigator_full_name>Ben Kappel</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

